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Abstract
Genetically modified mice carrying engrafted human tissues provide useful models to study human cell biology in
physiologically relevant contexts. However, there remain several obstacles limiting the compatibility of human cells within
their mouse hosts. Among these is inadequate cross-reactvitiy between certain mouse cytokines and human cellular
receptors, depriving the graft of important survival and growth signals. To circumvent this problem, we utilized a lentivirus-
based delivery system to express physiologically relevant levels of human interleukin-7 (hIL-7) in Rag2-/-cc-/- mice following
a single intravenous injection. hIL-7 promoted homeostatic proliferation of both adoptively transferred and endogenously
generated T-cells in Rag2-/-cc-/- Human Immune System (HIS) mice. Interestingly, we found that hIL-7 increased T
lymphocyte numbers in the spleens of HIV infected HIS mice without affecting viral load. Taken together, our study unveils a
versatile approach to deliver human cytokines to HIS mice, to both improve engraftment and determine the impact of
cytokines on human diseases.
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Introduction
The development of effective therapies against many of the most
widespread human diseases is hampered by a lack of adequate
model systems. Mice provide valuable in vivo models for basic
research but are generally inadequate for the study of human-
specific pathogens that infect cells of the human immune system.
One promising solution to this dilemma has been the development
of human-mouse chimeras that maintain the relatively low cost of
small animal models while allowing for the study of human
immune cells in a physiological setting. Human-mouse chimeras
have been under development for close to 40 years, and significant
progress has been made during this period[1]. However, the most
successful of these models typically requires the implantation of
multiple human embryonic tissues and are therefore labor
intensive and expensive to create[2,3].
Recently, two studies demonstrated that CD34+ human
progenitor cells isolated from either umbilical cord blood (CB)
or fetal liver could be injected into irradiated Rag2-/-cc-/-
newborn mice resulting in the development of a human immune
system (HIS)[4,5]. Upon reaching adulthood, these mice develop
both B and T lymphocytes that take residence in peripheral
lymphoid organs including the spleen and lymph nodes. Similar
engraftment has also been observed upon injecting CD34+ CB
cells into NOD/scid cc-/- (NSG) recipient mice[6,7]. These
models demonstrate a limited, yet promising, functional response
to immunization with tetanus toxoid or chicken ovalbumin
resulting in some production of antigen specific antibodies by
the graft[5,6]. Further work has demonstrated that these models
are susceptible to infection by human immunodeficiency virus
(HIV), and can therefore be used for the study of this human
pathogen[8,9]. Despite this progress, HIS mice have significant
limitations with respect to longevity of engraftment, production of
myeloid cell populations, and the consistency of immune cell
function in experimental replicates within a group[10]. Impor-
tantly, T cell populations in this model are slow to appear and are
greatly outnumbered by B lymphocytes until the mice are greater
than 6 months of age. These limitations necessitate the
improvement of the HIS mouse model if it is to become a
practical means of studying human immune responses or the
pathology of human diseases.
One approach towards overcoming these deficiencies is to
supplement human-mouse chimeras with cytokines to enhance
engraftment and immune function. Previous studies have
demonstrated improvements in human-mouse chimeras following
cytokine therapy, typically promoting increased engraftment of
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certain cell types[7,11,12]. These studies have used both direct
intravenous (iv) injection of recombinant cytokines and the
creation of transgenic mouse strains to express specific factors.
Both of these approaches have distinct disadvantages. iv injection
leads to fluctuating levels of the delivered cytokine and is labor
intensive. The transgenic approach is time consuming, especially
when multiple strains are to be tested. We have developed an
alternative cytokine delivery approach that can cheaply, easily,
reliably and stably deliver precise doses of human cytokines to
mice to improve the efficacy of human cytokine therapy, and
provide greater versatility.
Human Interleukin 7 (hIL-7) is a hematopoietic growth factor
implicated in the development of thymic T cells as well as
lymphoid homeostasis and survival in the periphery[13,14,15,16].
Upon binding to its cognate receptor IL-7Ra/CD127, signaling
proceeds through the JAK-STAT pathway leading to activation of
STAT5[17]. IL-7Ra signaling also regulates different BCL2
family members that are important regulators of cell survival[18].
Due to its profound impact on the homeostatic levels of T cells and
lack of toxicity in vivo, IL-7 therapy is currently being used in
clinical trials as a means to bolster T cell levels in lymphopenic
individuals[19,20,21]. Because IL-7 is normally produced by
stromal tissue and not immune cells[22], HIS mice are deficient in
the human IL-7 signal. These features give exogenous delivery of
hIL-7 the potential to improve the HIS mouse model.
In the present study, we have established a lentiviral vector-
based platform for delivery of human cytokines to HIS mice with
the long-term goal of improving human cell engraftment, diversity
and functional capacity in this model. We have initially focused on
delivering hIL-7 and found that super-physiological levels of hIL-7
could be produced and maintained for up to 6 months following a
single injection of lentiviral vector encoding this cytokine.
Adoptive transfer of human T lymphocytes into Rag2-/-cc-/-
mice after they had received the hIL-7 expressing lentivector led to
their homeostatic proliferation and expansion to higher levels
compared to control conditions. Similar increases in T cell
numbers were also observed in HIS mice that received the hIL-7
lentivector, and this correlated with higher expression of BCL2.
Finally, an increase in T cell numbers in HIS mice receiving the
IL-7 expressing lentiviral vector persisted in mice challenged with
HIV, suggesting that IL-7 could be therapeutically beneficial in
preserving CD4+ T cells during HIV infection.
Results
Increased survival of HIS mouse T cells following human
IL-7 treatment in vitro
We have established a HIS mouse model as described by Manz
and coworkers[5], finding that injection of purified CD34+ CB
cells into irradiated Rag2-/-cc-/- newborns can produce both B
and T lymphocytes as these mice mature. B cells consistently
dominate this model over the first 6 months, while CD3+ T
lymphocytes are found at relatively low levels in the peripheral
blood and spleens of these mice despite good numbers of
developing T cells in the thymus (Figure 1a). Based upon these
observations, we hypothesized that important human T cell
growth factors might be missing from this system. Among such
factors, IL-7 has been shown in both mice and humans to promote
T cell survival and homeostatic proliferation[13,14,15,16]. Fur-
thermore, because this factor is produced by non-hematopoietic
stromal cells it is not supplied by the engrafted human immune
cells[22].
We first tested whether T cells that develop in HIS mice express
the receptor for IL-7 by flow cytometry and observed expression
levels similar to those found on normal human T cells in the
peripheral blood (Figure 1b). Next, we treated both splenocytes
(16106 RBC-depleted) and lymph node cells (56105) from HIS
mice with increasing amounts of recombinant hIL-7 (replenished
on day 4) and observed a dose dependent increase in the survival
of both CD4+ and CD8+ T cells in vitro by day 7 based on 7-AAD
staining (Figure 1c). This demonstrates that human T cells
maturing in HIS mice are responsive to hIL-7.
Systemic delivery of hIL-7 to Rag2-/-cc-/- mice using a
lentiviral vector
Lentiviral vectors have been used for long term systemic
expression of genes in mice[23], and we therefore tested whether
hIL-7 could be delivered to immunodeficient mice using such an
approach. To this end we cloned the hIL-7 or luciferase (luc)
genes into a lentiviral construct (Figure 2a), produced virus, and
injected different amounts of hIL-7 or luc expressing virus
intravenously into Rag2-/-cc-/- mice. Imaging of mice receiving
the luc expressing lentivirus showed strong luciferase signal
localized primarily to liver, bone marrow and spleen (Figure 2b)
that was not present prior to transduction (Figure S1). In the
serum we detected high levels of hIL-7 by ELISA, which were
sustained for the entire six-month period of analysis (Figure 2c).
Furthermore, the levels of hIL-7 were dependent upon the
amount of lentivector injected for the first 2 months, indicating
that the expression levels can be controlled. These data
demonstrate that hIL-7 can be delivered to the immunodeficient
mouse strains used as hosts for human immune system grafts and
that expression is stable long-term. Additionally, intravenous
administration of lentivirus causes infection of tissues known to be
enriched in human immune cells, including the spleen and bone
marrow[5], or which function as an endogenous source of IL-7,
such as the liver[22].
Lentiviral vector delivery of hIL-7 to Rag2-/-cc-/- mice
promotes homeostatic proliferation of adoptively
transferred human T cells
Having successfully produced stable levels of hIL-7 in Rag2-/-
cc-/- mice following lentiviral vector injection, we next
investigated whether hIL-7 produced by this method could
impact human T cell survival as had been previously reported.
Adult Rag2-/-cc-/- mice were injected with two different doses of
the hIL-7 lentivector or control luc vector and hIL-7 expression
was assayed in the mouse serum two weeks later. At this time
point, we observed dose dependent levels of hIL-7 in mice
receiving the hIL-7 producing lentiviral vector and no detectable
hIL-7 in control mice (Figure 3a). Human peripheral blood
mononuclear cells (PBMCs) were CFSE labeled and injected
intravenously into these mice and allowed to expand for 7 days.
Spleens were removed and T cell populations were quantified by
flow cytometry. We observed a dose dependent increase in
human CD3+ T cell populations in hIL-7 expressing mice as
compared to mice expressing luciferase, and found that this
increase occurred in both CD4+ and CD8+ T cell populations
(Figure 3b and Figure S2). Because these cells were labeled with
CFSE prior to injection we analyzed the intensity of dye labeling
to determine the extent of their proliferation. Consistent with
hIL-7 driving homeostatic proliferation of T cells, we saw a dose
dependent decrease in CFSE intensity that inversely correlated
with hIL-7 expression (Figures 3c and 3d). These data
demonstrate that delivery of hIL-7 by a lentiviral vector can
increase the number of T cells in Rag2-/-c-/- mice by enhancing
proliferation.
Lentiviral Delivery of hIL-7
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Lentiviral delivery of human IL-7 to HIS mice expands
human T cell populations in the peripheral blood
Our adoptive transfer experiments indicated that hIL-7 could
improve human T cell populations in chimeric mice, and
suggested that this cytokine acts on the mature T cell populations
found in PBMCs. As described above, CD34+ CB derived HIS
mice have low levels of mature human T lymphocytes in their
periphery. Thus, we tested the impact of lentivirus delivered hIL-7
on T cell numbers in HIS mice. A cohort of HIS mice was
screened for human cell engraftment at 6 weeks of age (Figure 4a).
Upon reaching 8 weeks of age, HIS mice were given high and low
doses of the hIL-7 or luc control lentivectors, which again led to
dose dependent expression of hIL-7 (Figure 4b). Of note, we did
not detect any hIL-7 in engrafted HIS mice not receiving the hIL-
7 expressing vector, demonstrating the inability of the graft to
provide this cytokine. Peripheral blood B and T cell numbers were
assessed periodically until 18 weeks of age (Figure 4c). Mice
expressing hIL-7 showed a significant increase in the ratio of
peripheral blood T cells to B cells when compared to luciferase
expressing controls by 18 weeks of age (Figure S3). Interestingly,
mice receiving the higher dose of lentivirus developed high levels
of T-cells significantly faster than the low dose group (evident by
Figure 1. HIS mouse T cells express the IL-7Ra and exhibit increased viability in response to hIL-7 in vitro. a. Human immune cell
populations were analyzed in lymphoid tissues from 20 week old HIS mice by flow cytometry to determine the extent of T and B cell engraftment.
b. Peripheral blood from HIS mice or normal human donors was stained with either fluorophore-conjugated isotype control (clear histogram) or anti-
hIL-7Ra antibody (grey histograms) and analyzed by flow cytometry. c. HIS mouse splenocytes (16106) or lymph nodes cells (56105) were cultured in
increasing amounts of hIL-7 for 7 days. Cells were stained with antibodies against CD3, CD4 or CD8 as well as 7-AAD and analyzed by flow cytometry
to quantify the number of live cells of each subtype.
doi:10.1371/journal.pone.0012009.g001
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16 weeks of age) and reached a much higher level than the control
and low dose groups by week 18. Importantly, blood from 18 week
old hIL-7 expressing mice more closely resembled the T cell – B
cell ratio observed in normal human blood than that of control
mice (Figure 4d). Finally, we used flow cytometry to determine
which T cell subsets were expanded by hIL-7 (Figure 4e). While
hIL-7 led to marginally elevated human cell engraftment overall as
compared to control mice, the relative proportions of CD4, CD8,
naı¨ve and memory phenotype T cells in the peripheral blood of
hIL-7 expressing mice was largely unchanged by hIL-7, suggesting
that all T cell populations were expanded. Of note, the high but
not low dose group of hIL-7 mice had marginally elevated effecter
Figure 2. Delivery of hIL-7 to Rag2-/-cc-/- using a lentiviral vector. Schematic of the lentiviral vector used to deliver hIL-7 or luciferase.
b. Expression of luciferase was assayed using Xenogen imaging two months after intravenous injection of Rag2-/-cc-/- mice with 26108 infectious
units of luciferase expressing lentiviral vector. Localized expression from spleen (SP), bone marrow (BM), and liver (LV) are illustrated. c. Expression of
hIL-7 was assayed for six months in the serum of Rag2-/-cc-/- mice following a single intravenous injection of either 16108 or 46108 infectious units
of IL-7 expressing lentiviral vectors. Four mice were used per group, and the average and SEM are shown.
doi:10.1371/journal.pone.0012009.g002
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T cell populations in the peripheral blood compared to control
mice. Thus, hIL-7 can improve the overall T cell levels in the
peripheral blood of HIS mice.
IL-7 expands splenic lymphoid follicles and increases
both T cell numbers and BCL2 expression
We next examined whether hIL-7 impacted lymphoid tissues in
HIS mice. Upon dissection, we observed modest splenomegaly in
hIL-7 expressing mice compared to controls (Figure 5a), a finding
that has been observed in people undergoing hIL-7 treatment in a
clinical trial[21]. Hematoxylin and eosin staining on fixed spleen
sections on demonstrated, on average, larger lymphoid follicles in
hIL-7 treated mice (Figure 5b). Upon analyzing splenocytes by
flow cytometry we observed a marked increase in the percentage
of human T cells in the spleens and mesenteric lymph nodes of
hIL-7 expressing mice but found that the CD4/CD8 ratio was not
perturbed by IL-7 (Figure 5c). The absolute numbers of different
cell types in the spleen were also determined and T cells were
found to be elevated in IL-7 vs. control spleens (Figure 5d).
Immunohistochemistry showed increases in the number of CD3+
T cells in splenic sections of hIL-7 expressing HIS mice as
compared to controls, yet roughly equal densities of CD20+ B cells
Figure 3. Lentiviral vector delivery of hIL-7 promotes homeostatic proliferation of adoptively transferred human T cells in Rag2-/-
cc-/- mice. a. Serum concentrations of hIL-7 detected by ELISA three weeks after intravenous administration of 96107 or 1.76108 IU of lentivirus
expressing either luciferase or hIL-7. b. The percentage of CD3+, CD4+ or CD8+ T cells of live splenocytes following one week post transfer of 26107
CFSE labeled human PBMCs into Rag2-/-cc-/- mice from A. c. Average mean fluorescence intensity (MFI) of CFSE measured by flow cytometry in T-cell
subsets quantified in B. Four mice were used per group, and the average and SEM are shown. d. Representative histograms showing CFSE loss by
CD3+, CD4+ or CD8+ adoptively transferred T cells from mice receiving the control vector, low dose hIL-7 or high dose hIL-7.
doi:10.1371/journal.pone.0012009.g003
Lentiviral Delivery of hIL-7
PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12009
Figure 4. Lentiviral vector delivery of hIL-7 to HIS mice improves T cell levels in the peripheral blood. a. Total human CD45+ cell
engraftment in peripheral blood of cohort of mice used in this experiment prior to separation into treatment groups. b. Serum concentrations of hIL-
7 detected by ELISA at 18 weeks of age in mice receiving intravenous low (16108 IU) or high (56108 IU) dose lentivirus expressing either luciferase or
hIL-7. c. HIS mice were injected with 16108 (low dose) or 56108 (high dose) hIL-7 or luciferase expressing lentiviral vectors at 8 weeks of age
(indicated by black arrow). The percentages of CD3+ and CD19+ peripheral blood cells (as a percentage of total human CD45+ cells) were determined
from 8 to 18 weeks of age by flow cytometry. 5–7 mice were used per group, and the average and SEM are shown.d. Proportion of CD3 and CD19
expressing cells in peripheral blood of a representative luciferase or hIL-7 expressing HIS mice at 18 weeks of age as compared to a normal human
Lentiviral Delivery of hIL-7
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in the two groups (Figure 5e, left). Staining for the pro-survival
factor BCL2 revealed elevated expression in spleens from hIL-7
expressing HIS mice, and overlapped with CD3+ T cells
(Figure 5e, right) indicating a mechanism by which T-cells are
expanded in the periphery of HIS mice expressing hIL-7. To
assess the impact of improved T-cell engraftment on the humoral
immune system, we assayed the serum levels of IgM and IgG and
found an increase in total IgM, but little difference in total IgG
concentrations in mice expressing hIL-7 (Figure 5f).
IL-7 maintains high T cell levels in the spleen during HIV
infection without boosting viral load
An important feature of HIS mice is their ability to be infected by
human-specific pathogens such as HIV, which depletes CD4+ T
cells following infection[8]. Because IL-7 can increase the survival of
T cells, we tested whether CD4+ T cells in HIS mice would be
rescued by IL-7 following infection by HIV. To this end, we
challenged hIL-7 expressing HIS mice with the CCR5-tropic HIV
strain JRCSF at 18 weeks of age. Mice were bled and the fraction of
CD4+ T cells (as a percentage of total CD3+ cells) in the peripheral
blood was determined by flow cytometry. We observed a drop in
CD4+ cells at both 3 and 6 weeks post-infection in both groups
compared to uninfected animals (Figure 6a). Interestingly, quanti-
tation of HIV genome copies in mouse serum six weeks post-
infection by Amplicor revealed equivalent infection levels in HIS
mice treated with either hIL-7 or control lentivirus (Figure 6b).
Spleens were analyzed at six weeks and the number of total human
cells (CD45+), T cells (CD3+, CD4+ and CD8+) and B cells
(CD19+) in the spleens of infected mice were determined by FACS.
Despite having equivalent systemic infection levels, hIL-7 treated
mice exhibited elevated numbers of human T cells in their spleens
compared to control mice (Figure 6c). Both groups had equivalent
numbers of human splenic B cells. Fixed splenic sections were also
stained for p24, and the number of HIV infected cells in a given area
of lymphoid follicle was determined (Figure 6d). Like the blood,
HIV infection of the spleen was similar between the groups. These
data suggest that IL-7 can increase overall T lymphocyte numbers
during HIV infection without affecting viral load.
Discussion
The present study demonstrates that lentiviral vectors can be
used to express cytokine genes in HIS mice following a single
intravenous injection. This approach enabled hIL-7 to be
expressed at consistent levels long-term, and improved human T
lymphocyte numbers in the HIS model. Increases in T cell
numbers occurred in all compartments analyzed, consistent with
IL-7 functioning as a mediator of homeostatic proliferation.
Additionally, the direct effects induced by IL-7 were entirely
confined to the human graft, because the common c chain
required for IL-7R signaling is deficient in the host mouse strain.
Our approach resulted in hIL-7 serum concentrations higher than
those found in healthy human adults, which ranges from 0.27 to
8.7 pg/ml (average 2.2 pg/ml), yet within the range of some HIV-
positive lymphopenic individuals (which can be up to 70 pg/ml)[24].
Our experiments found that the impact of hIL-7 on human T cells
was reduced in animals expressing lower concentrations of cytokine
(10–20 pg/ml vs. 100 pg/ml hIL-7). This suggests that the HIS
mouse model may require super-physiological levels of certain
cytokines to induce meaningful changes in cellular compartments.
The reasons for this are presently unclear, but it may reflect
insufficient niche specific expression of hIL-7, which may be higher
than systemic levels. Therefore, our expression platform might not
be producing enough hIL-7 to reach such locations in sufficient
quantities until we boost the overall systemic levels to super-
physiological concentrations. Alternatively, other human cytokines
not present in the HIS model might sensitize target cells to lower
amounts of IL-7, but this also remains to be determined. It is also
plausible that insufficient niche specific hIL-7 levels are the reason
why a recent study did not observe differences in HIS mouse
peripheral T cell levels following direct injection of recombinant hIL-
7[25]. In fact, an earlier approach in which an Fc-IL-7 fusion protein
was delivered via weekly injections led to increased T cell: B cell
ratios in the spleens of humanized NOD-scid cc-/- mice[7]. This
approach stabilized hIL-7 serum levels, resulting in a biological
impact similar to that observed following constant hIL-7 production
by our expression system in humanized Rag2-/-cc-/- mice.
We observed a direct correlation between vector dose and
cytokine expression indicating that lentiviral based cytokine delivery
can be easily adjusted to deliver a desired dose of cytokine.
Transgene expression was also highest in the liver, bone marrow
and spleen, consistent with an earlier study that used VSVG-
pseudotyped lentivirus to deliver human factor IX to non-chimeric
SCID mice[23]. This infection pattern exhibits significant overlap
with the tissues and organs engrafted by the human immune cells
such as spleen and bone marrow. Liver tissue was also efficiently
targeted, mimicking one of the natural sites of IL-7 production in
vivo. Given this overlap in infection and human cell engraftment
patterns, it may also be possible to deliver molecules in addition to
cytokines, such as transmembrane receptors, that require direct cell-
to-cell contact to mediate their effects. Furthermore, because the
technology to target lentiviral vectors to specific cell types in vivo is
making substantial progress[26], delivering molecules to specific
tissues in vivo may soon be feasible in the HIS model.
Recently, clinical trials have shown that hIL-7 can increase T cell
numbers in people, indicating a promising therapeutic role for this
cytokine[19,20,21]. Two of these studies examined HIV infected
patients undergoing HAART therapy, resulting in low viral loads in
these individuals and making it hard to assess the impact IL-7 on
HIV replication. Our HIS mouse experiments suggest that IL-7 can
improve T cell levels even in the absence of antiretroviral drugs, and
do so without boosting HIV titers. This finding highlights the utility
of HIS mice as models for human-specific disease.
IL-7 has been shown to function as an adjuvant in mice[27].
However, despite increased T cell numbers and lymphoid follicle
size in the spleen, hIL-7 expressing HIS mice had only limited
immune function similar to controls. Ovalbumin immunization
resulted in modest antigen specific IgM responses and virtually no
IgG production in both control as well as hIL-7 expressing HIS
mice (Figure S4a). Additionally, JR-CSF infected hIL-7 or control
mice did not develop any appreciable antibody responses to virus
antigens as determined by western blotting (Figure S4b), further
supporting our assessment that IL-7 expression alone was
insufficient to restore normal immune function. Despite its
inability to improve antigen specific immune responses, hIL-7 is
likely an important piece of the puzzle given that T cells play a
central role in immune responses to antigens. Consistent with this,
we observed increased total serum IgM levels in hIL-7 expressing
donor. e. For each mouse group, human cell engraftment was determined by calculating the percentage of human CD45+ cells of total CD45+ cells.
The percentage of CD3+ CD4+ and CD3+CD8+ T cells in the peripheral blood was also determined. CD3+ naı¨ve (CD27+CD45RA+), effector
(CD27+CD45RA-) and memory (CD27-CD45RA-) phenotype T cells were quantified by flow cytometry.
doi:10.1371/journal.pone.0012009.g004
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mice, suggesting that improved T-cell survival by hIL-7 resulted in
increased B-cell output. Beyond immune function, IL-7 did not
improve the mouse to mouse, or donor to donor, variability
observed in the HIS model, suggesting that additional cytokines
known to act on HSCs are likely necessary to impact overall
human cell engraftment. Importantly, the modular nature of our
system will permit the delivery of multiple cytokines at one time,
and therefore future studies will investigate the effect of various
cytokine combinations with the goal of enhancing human immune
cell development and function in the HIS model.
Figure 5. Lentiviral vector delivery of hIL-7 improves T cell levels in the spleens and lymph nodes of HIS mice, and increases BCL2
expression. Spleens were removed from hIL-7 (low dose group) or luciferase expressing mice and weighed. b. Splenic sections were H&E stained
(scale bar = 1 mm). c. Spleens and lymph nodes were processed into single cell suspensions and flow cytometry was used to analyze the percentage
of human CD3+ versus CD19+ cells in the different groups. CD3+ cells were analyzed to quantify CD4+ and CD8+ subsets. d. Absolute cell numbers
for the indicated lineages were determined using splenocytes from hIL-7 expressing or control mice. e. Serial splenic sections were stained with
antibodies against human CD3 (scale bar = 100 mm) or CD20 (scale bar = 100 mm), and another set with CD3 (scale bar = 100 mm) and BCL2 (scale
bar = 100 mm). f. Serum from both low and high dose hIL-7 expressing mice or luciferase controls was assayed to determine the concentrations of
total IgM or total IgG.
doi:10.1371/journal.pone.0012009.g005
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Materials and Methods
Ethics Statement
All animal experiments were approved by the Institutional Animal
Care and Use Committee (IACUC) and conducted in agreement with
NIH policy. Animal experiments were conducted under California
Institute of Technology IACUC protocols 1536-06T and 1547-08G.
Mice
Rag2-/-cc-/- mice on a Balb/c genetic background were used for
all mouse experiments. For adoptive transfer experiments, mice were
injected with 26107 PBMCs (AllCells) that were first labeled with
CFSE. HIS mice were created as described[5]. In brief, 1.56105
highly purified CD34+ CB stem cells (AllCells) were injected into the
livers of irradiated (400 Rads) newborn pups within 24 hours of birth.
Human cell engraftment was routinely determined by analyzing the
ratio of human to mouse CD45+ cells in the peripheral blood at 6–8
weeks of age. Each experiment was performed using mice created
from the same CD34+ cell donor population.
Cell culture
T lymphocytes harvested from the spleen and lymph nodes of
HIS mice were cultured in RPMI medium with 10% FBS and 1%
Penicillin-Streptomycin. Cells were incubated in a humidified
incubator (5% CO2) at 37 C. Recombinant hIL-7 (Ebiosciences)
was added to the medium on day 0 and replenished on day 3 of
Figure 6. Higher CD3+ Splenic T cell numbers in HIV infected HIS mice expressing hIL-7. IL-7 or luciferase expressing HIS mice were
infected with the HIV strain JR-CSF and peripheral blood was assayed by flow cytometry to determine the percentage of CD4+ of CD3+ human T cells.
b. The HIV genome copy number in the peripheral blood plasma from the two groups of mice was quantified following 6 weeks of infection. c. The
human CD45+, CD3+, CD4+, CD8+ and CD19+ splenocyte numbers were quantified by FACS 6 weeks after infection by HIV. d. Fixed Spleen sections
from HIV infected luc and hIL-7 mice were stained for p24 (left, scale bar = 100 mm). The number of p24 positive cells in a given area (1 mm2) of a
lymphoid follicle was determined (right). Data represent 8–9 mice per group, and the average and SEM are shown.
doi:10.1371/journal.pone.0012009.g006
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culture, and cell viability was determined by staining for specific T
cell surface markers (CD3, CD4 and CD8) and positivity for 7-
AAD (eBioscience and Becton Dickinson).
Lentiviral production and infection of HIS mice
Sequences encoding hIL-7 or luciferase were cloned into the
pHAGE vector system. Experiments were performed using either
pHAGE1 or pHAGE6 vector backbones containing identical
transgenes driven from an internal CMV promoter for high and
low doses respectively. Both vectors are third-generation, self-
inactivating lentiviral vector backbones based on pHRST [28,29].
Briefly, the StuI fragment of pHRST containing a complete viral
genome was ligated into the pUC19 backbone to remove
exogenous flanking genomic sequences. PCR-cloning was em-
ployed to introduce restriction sites flanking the promoter and
transgene to facilitate subsequent cloning. Further modifications
were made to pHAGE6 to remove extraneous viral sequences with
no effect on virus function (A.B., to be published elsewhere).
Lentivirus was produced by transient transfection of 293T cells
with virus backbone and expression plasmids carrying helper
proteins. Briefly, 306106 293T cells were transfected with 40 ug of
DNA using TransIT-293 reagent (Mirus Bio, Madison WI)
according to manufacturer’s instructions. Viral supernatants were
collected beginning at 48 hours post-transfection and every
12 hours following for a total of 4 collections. Supernatants were
subjected to ultracentrifugation in a Beckman SW28 rotor at
16,500rpm for 1.5 hours at 4C and pelleted virus was resuspended
in growth media. Viruses were titered by standard means using
flow cytometry of infected 293T cells to determine infectious units
per mL. HIS mice were injected retro-orbitally with 200 uL of
PBS containing the specified dose of virus per mouse. Following
viral infection and integration, transcripts were initiated from an
internal CMV promoter, carried the ZsGreen fluorescent protein
downstream of an IRES element and contained a WPRE.
Flow Cytometry
Blood was obtained via retro-orbital bleeding of anesthetized
mice, or spleens and lymph nodes were removed from euthanized
animals, homogenized, and passed through a 40 uM filter to
create a single cell suspension. RBCs were lysed using RBC lysis
solution, Fc receptors blocked using anti-mouse CD16/32
antibodies (eBioscience), and single cell suspensions were stained
with specific antibodies using FACS buffer (1xPBS, 2% FBS, 0.1%
BSA and 0.1% Sodium Azide). The following antibodies were
used: anti-human CD3, CD4, CD8, CD19, CD45, CD127,
CD27, CD45RA and IGM (eBioscience). Anti-mouse CD45.2 was
also used to identify mouse white blood cells (eBioscience).
Immunohistochemistry
Spleens were fixed in formaldehyde and embedded in paraffin
by standard histological protocols. They were then sectioned and
stained with H&E or immunohistochemistry was carried out with
anti-human CD3, CD20 or BCL2. Anti-p24 antibodies were used
to detect HIV. Stained sections were then visualized using an
Olympus BX-41 light microscope and images captured and
processed using SPOT imaging software. For quantification of p24
staining, ten 400X fields were counted for cells with definitive
cytoplasmic staining. These were then presented as p24+ cells/
mm2.
HIV infections
HIV strain JRCSF (CCR5-tropic) was administered to HIS
mice via i.p. injection of 2880 ng of p24 as quantified by ELISA in
a volume of 200 ml. HIV genome copy numbers in the peripheral
blood were determined using Amplicor (Roche).
Ovalbumin Immunization
Balb/c or HIS mice previously receiving high dose luciferase or
hIL-7 lentivirus were immunized with 100 ug Ovalbumin protein
(Sigma) prepared with alum prior to IP injection. Serum samples
were collected 1 week post immunization and frozen for future
analysis. Mice were boosted 2 weeks after the initial immunization
with a second injection of 100 ug of Ovalbumin in alum and
serum was collected 1 weeks later (3 Weeks from initial
immunization). Serums were serially diluted and applied to ELISA
plates coated with Ova. Detection of Ova specific antibodies was
achieved using anti-mouse IgM or IgG (Balb/C Samples) or anti-
human IgM or IgG (HIS samples) HRP-conjugated antibodies.
The absorbance at each dilution was measured and those in the
linear range were used to calculate fold differences between the
pre- and post-immunization samples.
HIV-specific Western blot
Serum collected from mice previously infected with JR-CSF 7
weeks post-challenge was analyzed using the GS HIV-1 Western
Blot system (BioRad) according to manufacturer’s instructions.
Briefly, serums were diluted and incubated with nitrocellulose
strips containing pre-blotted HIV proteins prior to washing and
enzymatic detection of bound human antibodies.
Supporting Information
Figure S1 Luciferase imaging prior to intravenous administra-
tion of lentiviral vector. Expression of luciferase was assayed using
Xenogen imaging prior to intravenous injection of Rag2-/-cc-/-
mice with lentiviral vector expressing luciferase. The same
representative mouse shown in Figure 2b is shown prior to
transduction.
Found at: doi:10.1371/journal.pone.0012009.s001 (2.29 MB TIF)
Figure S2 Lentiviral vector delivery of hIL-7 promotes homeo-
static proliferation of adoptively transferred human T cells in
Rag2-/-cc-/- mice. Rag2-/-cc-/- mice previously transduced with
luciferase or hIL-7 expressing lentivirus were injected with 26107
CFSE labeled human PBMCs. One-week post transfer, the
numbers of CD3+, CD4+ and CD8+ T cells were counted from
spleens to determine the effect of hIL-7 during adoptive transfer.
Found at: doi:10.1371/journal.pone.0012009.s002 (0.17 MB TIF)
Figure S3 Lentiviral vector delivery of hIL-7 to HIS mice
improves T cell ratios in peripheral blood. HIS mice were injected
with 16108 (low dose) or 56108 (high dose) hIL-7 or luciferase
expressing lentiviral vectors at 8 weeks of age. The ratio of CD3+
to CD19+ cells detected in peripheral blood were determined from
8 to 18 weeks of age by flow cytometry. 5–7 mice were used per
group, and the average and SEM are shown.
Found at: doi:10.1371/journal.pone.0012009.s003 (0.45 MB TIF)
Figure S4 Assessment of antigen specific humoral responses in
HIS mice expressing hIL-7. a. Wt Balb/c or HIS mice expressing
luciferase or hIL-7 were immunized with ovalbumin protein and
serums were subjected to ELISA following initial exposure
(1 week) or post-boost (3 weeks) to quantify the fold increase in
Ovalbumin specific IgM (top) or IgG (bottom) relative to pre-
immune levels for each animal. Dashed lines are drawn at the level
of no fold change. b. Serums from HIS mice expressing luciferase
or hIL-7 infected with JR-CSF HIV for 6 weeks were subjected to
western blot analysis to detect HIV specific antibody responses.
Found at: doi:10.1371/journal.pone.0012009.s004 (3.98 MB TIF)
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